StockWatch
·

Sai Life Sciences Ltd Q2 FY27 Results

SAILIFEQ2 FY27 Results
Filing
Result:Good· Market: Surged#Margin expansion#Broad based

Outlook: Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue658.5918.8%22.5%
Total Income662.5518.8%19.9%
Expenditure531.2715.5%20.5%
PBT131.2834.0%17.2%
Net Profit98.3234.2%17.3%
OPM28.30%1.60pp1.17pp
NPM14.84%1.70pp0.33pp
EPS4.6333.8%15.5%
View full financials

CDMO/pharma services revenue grew a strong 22.5% YoY with OPM expanding to 28.3% from 27.1%, driven by core business rather than one-offs, though PAT growth (17.3%) lagged revenue on lower other income and higher tax.

SAI LIFE SCIENCES · Q2 FY-2027 · THE VERDICT

Growth beats guide, but the rally has run to ATH on margin headwinds and capex caution

Sai delivered 22.5% revenue growth (beating 15–20% guidance) and 28.3% OPM (in-line), validating the integrated CRDMO strategy. But raw material cost inflation is eating margins, 225 KL capacity slipped 6 months, and the stock is at all-time high with overbought technicals—the rally deserves skepticism.

12 Nov 2026 · 6 min read

Sai Life Sciences delivered a quarter that passes the headline test—22.5% revenue growth beats the 15–20% long-term guidance, OPM is stable at 28.3% (within 28–30% range), and PAT rose 17.3% YoY. The integrated CRDMO strategy is being validated: two major pharma partnerships are now live, biotech enquiries are picking up, and headcount is scaling (+1,200 in first half to ~4,400). But the earnings quality is muddier. Raw material costs from Middle East supply constraints are rising (solvents, chemicals), and the company acknowledged these will impact near-term margins until full recovery through customer contracts is realized. A 6-month push-out on the 225 KL CDMO capacity (from Q4 FY27 to Q3 FY28) signals execution caution. And the stock is at all-time high with RSI at 80.5 (overbought), while FII have trimmed 1.52 percentage points—the smart money is selling into the rally.

Revenue growth

22.5%

YoY; beats 15–20% guide

OPM

28.3%

Flat YoY, within 28–30% range

PAT growth

17.3%

YoY; steady, below revenue

Capex H1 FY27

₹621 Cr

On track for ₹1,100–1,300 Cr FY27

Where the margin pressure is hiding

OPM looks stable at 28.3% YoY, and the call data confirms this is within guidance. But the call also flagged that Middle East supply constraints have driven up solvents and chemicals costs, and while the company is working customer contracts to recover these, the full pass-through hasn't landed in this quarter's PAT yet. That means Q3 is the proving ground: if recovery mechanisms work, margins hold; if they don't, OPM compresses. The company is hedging: it says costs are "modest" and "being recovered," but analysts pressed hard on the timeline. Management deferred specifics. For a holder, this is a near-term lever on earnings quality.

What changed on this call

  • Integrated CRDMO validated: 2 major pharma partnerships now live (discovery→dev→commercial), up from 'potential' prior

  • Biotech funding cycle returning: Uptick in enquiries observed; recovery expected 18–24 months out

  • 225 KL CDMO capacity pushed 6 months: Q4 FY27 → Q3 FY28 per customer priorities

  • Raw material inflation: Middle East situation spiking solvents/chemicals; recovery in progress

  • Headcount ramp: +1,200 in first half to ~4,400, validating integrated model scaling

The bull-bear ledger

  • Growth 22.5% beats 15–20% guidance; CRO +28%, CDMO +20%

  • Integrated CRDMO strategy validated: 2 pharma programs live, 5–7 evaluating

  • Biotech recovery beginning; enquiries uptick, expected 18–24 month ramp

  • Long-term tailwinds intact: China controls (COINS Act), India CDMO positioning

  • Largest customer ~12% of revenue; top 10 ~40–50% (concentration risk)

  • Raw material costs rising; recovery mechanisms not yet fully realized

  • 225 KL capacity delayed 6 months; capex execution flexibility signals caution

  • Partnership revenue undefined: 2 programs live, wallet share and ramp absent

  • Stock at all-time high, RSI 80.5 (overbought); FII trimming 1.52pp

Risks, ranked by how much they should concern a holder

Key risks in order of severity for a shareholder

Valuation and momentum at all-time high

High

Stock at ₹1918.6, all-time high, RSI 80.5 (overbought). FII reduced 1.52pp despite bullish fundamentals—smart money skeptical of valuation at the peak. Disappointment on margin recovery or partnership monetization triggers correction.

Customer concentration and pharma outsourcing consolidation

Medium

Largest customer ~12%, top 10 ~40–50%. Pharma outsourcing is consolidating. If a top customer exits, revenue impact is material. Integrated model aims to dilute risk but is early-stage and unproven.

Raw material cost pass-through delayed

Medium

Middle East crisis elevated solvents/chemicals costs. Q2 OPM stable, but full recovery not yet in PAT. If Q3 shows margin compression despite recovery efforts, earnings quality deteriorates.

Partnership monetization vague and slow

Medium

2 pharma programs live, but revenue ramp undefined. Competitors take multi-year ramps. If Sai's ramp is slower than expected or wallet share dilutes, growth outlook softens and margins compress.

Capex execution delays

Low

225 KL pushed 6 months. First phase (Bidar) on track. Slippage within broader plan, but flexibility suggests caution on customer visibility. Full-year capex reaffirmed; near-term risk low.

How the street is positioned

The stock rallied hard to all-time high, up 144.77% from the 52-week low, and sits well above all key moving averages (SMA20 ₹1539.83, SMA50 ₹1551.94, SMA200 ₹1227.6). Volume is increasing, technicals look extended (RSI 80.5 = overbought). The puzzle: despite the bullish call and growth beat, FII reduced their holding by 1.52 percentage points to 19.65%, while DII added 1.17pp to 32.71%. This is classic momentum-chasing by retail/domestic investors bumping into institutional skepticism. FII at 19.65% is near multi-year lows. The FII outflow despite bullish fundamentals signals the smart money sees valuation risk at all-time highs. A pullback would likely trigger FII re-entry; support is the 50-day and 200-day moving averages.

The debate

Bull case: Sai is the go-to India CRDMO for global pharma. 22.5% growth beats guidance; 2 major partnerships live and validate the integrated model. Biotech recovery is beginning. China export controls and India positioning create structural tailwinds. CRO +28% for 8 quarters. Guidance for 15–20% long-term growth is conservative, likely under-delivery. Hold for re-rating on partnership scale.

Bear case: Stock at all-time high with overbought technicals (RSI 80.5), FII exiting despite bullish headlines. Valuation assumes partnership monetization at scale, but 2 programs are early-stage and competitors take multi-year ramps. Margin recovery from raw material costs is not guaranteed. Largest customer ~12%, concentration real. Capex delays signal execution caution. Integrated model unproven on wallet share. Risk/reward skewed against you at ATH.

The honest read: This is a good company with a validated strategy (2 pharma programs live) growing faster than guidance (22.5% vs. 15–20%), but the stock has run to all-time high on momentum, detached from clarity on margin recovery or partnership monetization. The quarter proved the integrated model works; it did not prove scale or monetization. Hold if you own it; wait for pullback to buy. Q3 will tell if margins recover (OPM recovery despite raw materials), if partnership commentary improves (even unquantified), and if capex tracks (225 KL timeline toward Q3 FY28). If those land, re-rating higher is possible. If not, downside is real from ATH. Prefer a pullback entry or hold-at-levels for existing positions.

What to watch next
  • 1 · Q3 FY27 margin recovery

    The test for raw material cost pass-through. If OPM recovers to 28.3%+ despite Middle East solvents inflation, margin recovery story is intact. If compressed, cost inflation is stickier than expected. Single most important metric for Q3.

  • 2 · Partnership revenue ramp

    2nd pharma integrated program expected 'fully functional' in Q3 FY28. Even if unquantified, qualitative color on customer comfort, wallet share, and trajectory validates the business model. Vague commentary keeps valuation at risk.

  • 3 · 225 KL commissioning progress

    On track for Q3 FY28? Further delays signal execution caution. On-time delivery confirms capex discipline and customer confidence.

Sai delivered a solid quarter—growth beats, strategy validated, partnerships live. But earnings quality faces near-term headwinds (raw material costs), execution caution is evident (225 KL delayed), and valuation at all-time high is vulnerable. The honest read is steady execution, not a step-change. Watch Q3 OPM: that's the lever on margin recovery, and it will tell if the rally is justified or stretched. For holders: no urgency to exit, but wait for clarity. For prospective buyers: wait for pullback or Q3 proof. The 50-day moving average (₹1539.83) is key support; a break below signals momentum has fully reversed. The number to track is organic margin recovery—not the topline beat.

Informational and educational content only. Not investment advice.